Featured Publications
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatientsUrine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight 2019, 4: e127456. PMID: 31092735, PMCID: PMC6542610, DOI: 10.1172/jci.insight.127456.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney diseasePrebiopsy diagnosisKidney biopsyKidney diseaseIL-9AIN diagnosisUrine TNFInterstitial nephritisSpecific T cell subsetsAcute tubular injuryDiabetic kidney diseaseIL-9 levelsTNF-α levelsT cell subsetsAddition of biomarkersPlasma cytokinesCytokine levelsTubular injuryHighest quartileMultivariable analysisCell subsetsUrinary TNFBlood eosinophilsGlomerular diseaseMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activationUrine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis
Melchinger H, Calderon-Gutierrez F, Obeid W, Xu L, Shaw MM, Luciano RL, Kuperman M, Moeckel GW, Kashgarian M, Wilson FP, Parikh CR, Moledina DG. Urine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1284-1292. PMID: 35948365, PMCID: PMC9625093, DOI: 10.2215/cjn.04360422.Peer-Reviewed Original ResearchConceptsInterstitial fibrosis/tubular atrophyUrine uromodulinTubular atrophyThick ascending limbUrine albuminSerum creatinineKidney biopsyTubulointerstitial fibrosisMultivariable linear regression modelsTime of biopsyKidney's thick ascending limbAcademic medical centerHuman kidney biopsiesKidney tubulointerstitial fibrosisTubular healthMultivariable analysisHistologic featuresHistologic findingsHistologic changesKidney fibrosisIndependent associationFibrotic modelMultivariable modelMedical CenterMurine model
2024
The development of lateral flow devices for urinary biomarkers to assess kidney health
D Souza S, Obeid W, Hernandez J, Hu D, Wen Y, Moledina D, Albert A, Gregg A, Wheeler A, Philbrook H, Parikh C. The development of lateral flow devices for urinary biomarkers to assess kidney health. Scientific Reports 2024, 14: 8516. PMID: 38609491, PMCID: PMC11014899, DOI: 10.1038/s41598-024-59104-5.Peer-Reviewed Original ResearchConceptsLateral flow deviceInterleukin-9Development of lateral flow devicesUrinary biomarkersDetection antibody concentrationSerum creatinine levelsKidney healthPaired antibodiesEnzyme Linked Immunosorbent AssayCreatinine levelsKidney injuryKidney functionOsteopontinImmunosorbent assayAntibody concentrationsMeasured biomarkersKidneyReal-time changesBiomarkers
2023
APOBEC-1 deletion enhances cisplatin-induced acute kidney injury
Guo X, Blanc V, Davidson N, Velazquez H, Chen T, Moledina D, Moeckel G, Safirstein R, Desir G. APOBEC-1 deletion enhances cisplatin-induced acute kidney injury. Scientific Reports 2023, 13: 22255. PMID: 38097707, PMCID: PMC10721635, DOI: 10.1038/s41598-023-49575-3.Peer-Reviewed Original ResearchAnalysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury
Wen Y, Su E, Xu L, Menez S, Moledina D, Obeid W, Palevsky P, Mansour S, Devarajan P, Cantley L, Cahan P, Parikh C, Project K, Injury T. Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury. Science Translational Medicine 2023, 15: eade7287. PMID: 38091407, PMCID: PMC11405121, DOI: 10.1126/scitranslmed.ade7287.Peer-Reviewed Original ResearchThe ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events
Menez S, Wen Y, Xu L, Moledina D, Thiessen-Philbrook H, Hu D, Obeid W, Bhatraju P, Ikizler T, Siew E, Chinchilli V, Garg A, Go A, Liu K, Kaufman J, Kimmel P, Himmelfarb J, Coca S, Cantley L, Parikh C. The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events. Kidney International 2023, 104: 1194-1205. PMID: 37652206, PMCID: PMC10840723, DOI: 10.1016/j.kint.2023.08.007.Peer-Reviewed Original ResearchConceptsMajor adverse kidney eventsUEGF/CrUrinary epidermal growth factorAdverse kidney eventsChronic kidney diseaseEpidermal growth factorKidney eventsKidney failureEGF expressionUrinary EGF/CrAcute Kidney Injury studyGrowth factorIschemia-reperfusion injuryProportional hazards regressionTubular healthKidney atrophyObservational cohortHospitalized participantsTubular functionClinical findingsHazards regressionKidney diseaseClinical variablesProgressive atrophyUrinary EGFEvaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
Menez S, Coca S, Moledina D, Wen Y, Chan L, Thiessen-Philbrook H, Obeid W, Garibaldi B, Azeloglu E, Ugwuowo U, Sperati C, Arend L, Rosenberg A, Kaushal M, Jain S, Wilson F, Parikh C, Consortium T, Deng J, Atta M, Bagnasco S, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19. American Journal Of Kidney Diseases 2023, 82: 322-332.e1. PMID: 37263570, PMCID: PMC10229201, DOI: 10.1053/j.ajkd.2023.03.010.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Major adverse kidney eventsAdverse kidney eventsAdverse kidney outcomesAcute kidney injuryKidney eventsTumor necrosis factor receptor 1Necrosis factor receptor 1Plasma biomarkersKidney outcomesC-indexFactor receptor 1Hospitalized patientsCOVID-19KDIGO stage 3 acute kidney injuryDialysis-requiring acute kidney injuryStage 3 acute kidney injuryLong-term adverse health outcomesReceptor 1Long-term kidney dysfunctionAvailable blood samplesIdentification of patientsProportional hazards regressionAdverse health outcomesCOVID-19 hospitalizationLongitudinal biomarkers and kidney disease progression after acute kidney injury
Wen Y, Xu L, Melchinger I, Thiessen-Philbrook H, Moledina D, Coca S, Hsu C, Go A, Liu K, Siew E, Ikizler T, Chinchilli V, Kaufman J, Kimmel P, Himmelfarb J, Cantley L, Parikh C, Consortium T. Longitudinal biomarkers and kidney disease progression after acute kidney injury. JCI Insight 2023, 8: e167731. PMID: 36951957, PMCID: PMC10243801, DOI: 10.1172/jci.insight.167731.Peer-Reviewed Original ResearchConceptsAcute kidney injuryIschemic reperfusion injuryKidney disease progressionKidney injuryTubular healthDisease progressionChronic kidney disease (CKD) incidenceCox proportional hazards regressionMurine acute kidney injuryKidney disease incidenceUrine KIM-1Proportional hazards regressionCKD progressionCKD transitionUrine uromodulinIncident CKDComposite outcomeKidney atrophyProspective cohortReperfusion injuryHazards regressionKIM-1Prognostic valueMCP-1Initial insult
2022
Pre-operative kidney biomarkers and risks for death, cardiovascular and chronic kidney disease events after cardiac surgery: the TRIBE-AKI study
Vasquez-Rios G, Moledina D, Jia Y, McArthur E, Mansour S, Thiessen-Philbrook H, Shlipak M, Koyner J, Garg A, Parikh C, Coca S. Pre-operative kidney biomarkers and risks for death, cardiovascular and chronic kidney disease events after cardiac surgery: the TRIBE-AKI study. Journal Of Cardiothoracic Surgery 2022, 17: 338. PMID: 36567329, PMCID: PMC9790121, DOI: 10.1186/s13019-022-02066-4.Peer-Reviewed Original ResearchConceptsKidney injury molecule-1Cardiovascular eventsCardiac surgeryCKD eventsCohort studyPlasma kidney injury molecule-1Chronic kidney disease (CKD) incidenceKidney disease incidenceKidney function dataPre-operative concentrationsInjury molecule-1Evaluation of patientsHigh-risk adultsLong-term outcomesHigh-risk individualsTumor necrosis factor receptorNecrosis factor receptorKidney eventsMedian followPlasma sTNFR1Hazard ratioClinical outcomesKidney biomarkersPlasma biomarkersClinical covariatesSafety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original ResearchImmune-mediated tubule atrophy promotes acute kidney injury to chronic kidney disease transition
Xu L, Guo J, Moledina DG, Cantley LG. Immune-mediated tubule atrophy promotes acute kidney injury to chronic kidney disease transition. Nature Communications 2022, 13: 4892. PMID: 35986026, PMCID: PMC9391331, DOI: 10.1038/s41467-022-32634-0.Peer-Reviewed Original ResearchConceptsAcute kidney injuryKidney injuryT cellsChronic kidney disease transitionIschemia-reperfusion kidney injuryKidney disease transitionChronic kidney diseaseDepletion of neutrophilsGlomerular filtration rateT cell recruitmentTubular cell lossMacrophage persistenceProinflammatory neutrophilsTubule damageKidney atrophyContralateral kidneyNeutrophil numbersContralateral nephrectomyKidney diseaseTubule atrophyFiltration rateCell recruitmentMore macrophagesDay 14Day 5Clinically adjudicated deceased donor acute kidney injury and graft outcomes
Mansour SG, Khoury N, Kodali R, Virmani S, Reese PP, Hall IE, Jia Y, Yamamoto Y, Thiessen-Philbrook HR, Obeid W, Doshi MD, Akalin E, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Singh P, Weng FL, Moledina DG, Greenberg JH, Wilson FP, Parikh CR. Clinically adjudicated deceased donor acute kidney injury and graft outcomes. PLOS ONE 2022, 17: e0264329. PMID: 35239694, PMCID: PMC8893682, DOI: 10.1371/journal.pone.0264329.Peer-Reviewed Original ResearchConceptsDonor Acute Kidney InjuryAcute kidney injuryGraft failureAKI phenotypesKidney injuryUrine biomarkersLack of associationAKI casesGraft functionHigher DGFPotential kidneyGraft outcomeDeceased donorsOrgan utilizationMCP-1YKL-40Donor StudyEGFRDGFAncillary analysisAvailable chartsBiomarkersInjuryPhenotypeAssociation
2021
Rationale and design of the Kidney Precision Medicine Project
de Boer IH, Alpers CE, Azeloglu EU, Balis UGJ, Barasch JM, Barisoni L, Blank KN, Bomback AS, Brown K, Dagher PC, Dighe AL, Eadon MT, El-Achkar TM, Gaut JP, Hacohen N, He Y, Hodgin JB, Jain S, Kellum JA, Kiryluk K, Knight R, Laszik ZG, Lienczewski C, Mariani LH, McClelland RL, Menez S, Moledina DG, Mooney SD, O’Toole J, Palevsky PM, Parikh CR, Poggio ED, Rosas SE, Rosengart MR, Sarwal MM, Schaub JA, Sedor JR, Sharma K, Steck B, Toto RD, Troyanskaya OG, Tuttle KR, Vazquez MA, Waikar SS, Williams K, Wilson FP, Zhang K, Iyengar R, Kretzler M, Himmelfarb J, Project K, Knight R, Lecker S, Stillman I, Waikar S, Mcmahon G, Weins A, Short S, Hacohen N, Hoover P, Aulisio M, Cooperman L, Herlitz L, O’Toole J, Poggio E, Sedor J, Jolly S, Appelbaum P, Balderes O, Barasch J, Bomback A, Canetta P, d’Agati V, Kiryluk K, Kudose S, Mehl K, Radhakrishnan J, Weng C, Barisoni L, Alexandrov T, Ashkar T, Barwinska D, Dagher P, Dunn K, Eadon M, Ferkowicz M, Kelly K, Sutton T, Winfree S, Menez S, Parikh C, Rosenberg A, Villalobos P, Malik R, Fine D, Atta M, Trujillo J, Slack A, Rosas S, Williams M, Azeloglu E, He C, Iyengar R, Hansen J, Parikh S, Rovin B, Anderton C, Pasa-Tolic L, Velickovic D, Lukowski J, Oliver G, Ardayfio J, Bebiak J, Brown K, Campbell T, Campbell C, Hayashi L, Jefferson N, Koewler R, Roberts G, Saul J, Shpigel A, Stutzke E, Wright L, Miegs L, Pinkeney R, Sealfon R, Troyanskaya O, Tuttle K, Dobi D, Goltsev Y, Lake B, Zhang K, Joanes M, Laszik Z, Schroeder A, Sarwal M, Sigdel T, Balis U, Blanc V, He O, Hodgin J, Kretzler M, Mariani L, Menon R, Otto E, Schaub J, Steck B, Lienczewski C, Eddy S, Elder M, Hall D, Kellum J, Kruth M, Murugan R, Palevsky P, Randhawa P, Rosengart M, Sims-Lucas S, Stefanick M, Stull S, Tublin M, Alpers C, de Boer I, Dighe A, Himmelfarb J, Mcclelland R, Mooney S, Shankland S, Williams K, Blank K, Carson J, Dowd F, Drager Z, Park C, Sharma K, Zhang G, Bansal S, Venkatachalam M, Kermani A, Lee S, Lu C, Miller T, Moe O, Park H, Sambandam K, Sanchez F, Torrealba J, Robert T, Vazquez M, Wang N, Gaut J, Jain S, Vijayan A, Luciano R, Moledina D, Ugochukwu U, Wilson F, Alfano S. Rationale and design of the Kidney Precision Medicine Project. Kidney International 2021, 99: 498-510. PMID: 33637194, PMCID: PMC8330551, DOI: 10.1016/j.kint.2020.08.039.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseKidney Precision Medicine ProjectKidney biopsyKidney diseasePrecision Medicine ProjectKidney tissueMulticenter prospective cohort studyProtocol kidney biopsiesProspective cohort studyDeep clinical phenotypingPrecision medicine approachMedicine ProjectKidney injuryClinical characteristicsCohort studyClinical outcomesSubgroup analysisMorbid diseaseNovel therapiesPreventive strategiesClinical phenotypingDisease subgroupsToxic injuryPatients
2019
The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery
Mansour SG, Zhang WR, Moledina D, Coca SG, Jia Y, Thiessen-Philbrook H, McArthur E, Inoue K, Koyner JL, Shlipak MG, Wilson FP, Garg AX, Ishibe S, Parikh CR, Consortium T. The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery. American Journal Of Kidney Diseases 2019, 74: 36-46. PMID: 30955944, PMCID: PMC6591032, DOI: 10.1053/j.ajkd.2019.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersCardiac Surgical ProceduresCreatinineEndpoint DeterminationFemaleHumansKidneyMaleMiddle AgedNeovascularization, PhysiologicOutcome Assessment, Health CarePostoperative ComplicationsProspective StudiesReceptors, Vascular Endothelial Growth FactorRisk AssessmentUnited StatesVascular Endothelial Growth Factor AConceptsAcute kidney injuryCardiac surgeryAKI durationKidney injuryProangiogenic markersAngiogenesis markersOutcomes of AKILong-term outcomesPlasma VEGF concentrationsTRIBE-AKI cohortAntiangiogenic markersCause mortalityPreoperative concentrationsHospital dischargeProcess of angiogenesisMarker levelsVEGFR1 levelsPGF concentrationsHigher oddsMortality riskHigh riskLower oddsVEGF concentrationsAngiogenic markersSurgery
2018
Treatment of Drug-Induced Acute Tubulointerstitial Nephritis: The Search for Better Evidence
Moledina DG, Perazella MA. Treatment of Drug-Induced Acute Tubulointerstitial Nephritis: The Search for Better Evidence. Clinical Journal Of The American Society Of Nephrology 2018, 13: 1785-1787. PMID: 30397028, PMCID: PMC6302332, DOI: 10.2215/cjn.12001018.Commentaries, Editorials and LettersKidney Biopsy–Related Complications in Hospitalized Patients with Acute Kidney Disease
Moledina DG, Luciano RL, Kukova L, Chan L, Saha A, Nadkarni G, Alfano S, Wilson FP, Perazella MA, Parikh CR. Kidney Biopsy–Related Complications in Hospitalized Patients with Acute Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2018, 13: 1633-1640. PMID: 30348813, PMCID: PMC6237071, DOI: 10.2215/cjn.04910418.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseBiopsy-related complicationsLow platelet countHospitalized patientsNonhospitalized patientsKidney biopsyKidney diseasePlatelet countHigher BUNFemale sexRisk factorsLarge-sized hematomaStage 1 AKIRate of complicationsProcedure-related bleedingLarger needle gaugeAbdominal ultrasonographyBiopsy cohortBlood transfusionAngiographic interventionMultivariable analysisPostbiopsy complicationsMultivariable associationsHigh riskTransfusion
2016
PPIs and kidney disease: from AIN to CKD
Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. Journal Of Nephrology 2016, 29: 611-616. PMID: 27072818, DOI: 10.1007/s40620-016-0309-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute interstitial nephritisProton pump inhibitorsChronic kidney diseaseKidney diseaseDrug-induced acute interstitial nephritisExcellent overall safety profileHigher CKD riskSystemic allergic manifestationsAcute kidney injuryAdverse renal eventsGlomerular filtration rateOverall safety profilePopulation-based studyMillions of patientsAIN diagnosisRenal eventsCKD riskKidney injuryAllergic manifestationsInterstitial nephritisMedian timeSafety profileDrug initiationKidney failurePump inhibitors